These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23642976)

  • 21. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
    Pickar D; Bartko JJ
    Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia?
    Jiménez-Cornejo M; Munizaga G; Aceituno D
    Medwave; 2016 Dec; 16(Suppl5):e6614. PubMed ID: 27922589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
    Henderson DC; Kunkel L; Nguyen DD; Borba CP; Daley TB; Louie PM; Freudenreich O; Cather C; Evins AE; Goff DC
    Acta Psychiatr Scand; 2006 Feb; 113(2):142-7. PubMed ID: 16423166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study.
    Souaiby L; Gauthier C; Rieu C; Krebs MO; Advenier-Iakovlev E; Gaillard R
    Schizophr Res; 2017 Oct; 188():89-91. PubMed ID: 28139358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
    Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.
    Nielsen J; Emborg C; Gydesen S; Dybbro J; Aagaard J; Haderup K; Glyngdal P; Fabricius S; Thode D; Lublin H; Andersen T; Damkier P; Taylor D
    J Clin Psychopharmacol; 2012 Apr; 32(2):173-8. PubMed ID: 22367659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period.
    Ravanic DB; Dejanovic SM; Janjic V; Jovic SD; Milovanovic DR; Jakovljevic V; Pantovic V; Ravanic B; Pantovic M; Pantovic MM
    Arq Neuropsiquiatr; 2009 Jun; 67(2A):195-202. PubMed ID: 19547808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study.
    Silver H; Kushnir M; Kaplan A
    Biol Psychiatry; 1996 Oct; 40(7):671-4. PubMed ID: 8886304
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of the adverse effects of clozapine.
    Young CR; Bowers MB; Mazure CM
    Schizophr Bull; 1998; 24(3):381-90. PubMed ID: 9718630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
    Zink M; Knopf U; Henn FA; Thome J
    Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.
    Flynn SW; MacEwan GW; Altman S; Kopala LC; Fredrikson DH; Smith GN; Honer WG
    Pharmacopsychiatry; 1998 Jan; 31(1):25-9. PubMed ID: 9524981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of treatment resistant schizophrenia unresponsive to clozapine.
    Barnes TR; McEvedy CJ; Nelson HE
    Br J Psychiatry Suppl; 1996 Dec; (31):31-40. PubMed ID: 8968653
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.
    Behdani F; Hebrani P; Rezaei Ardani A; Rafee E
    Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia.
    Shang DW; Li LJ; Wang XP; Wen YG; Ren YP; Guo W; Li WB; Li L; Zhou TY; Lu W; Wang CY
    Ther Drug Monit; 2014 Jun; 36(3):378-86. PubMed ID: 24342896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.